Skip to content

Satellite Symposia

AMCP Nexus 2020 allows non-commercial, grant-supported satellite symposia in conjunction with the meeting. These continuing education activities are developed by medical education organizations. Satellite Symposia offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit.

All Satellite Symposia will be held at the MGM Grand Las Vegas Conference Center from Tuesday, Oct. 20 through Friday, Oct. 23.  Any pre-registration taken for these activities is for planning purposes only and does not guarantee a seat. Seating is limited and provided on a first-come, first-served basis. We recommend an early arrival. For additional information about a specific symposium, please contact the program manager listed.

Additional symposia to be added, so keep an eye on this page for more information!

Please email any satellite questions to satellitesymposia@amcp.org.

Tuesday, Oct. 20 | 10:30am – Noon


The Evolving Management of Psoriatic Disease: A Guide for Managed Care and Specialty Pharmacy Professionals

Provided jointly by Postgraduate Institute for Medicine and Impact Education, LLC.
Supported by an independent educational grant from UCB.
Continuing education credit available for pharmacists and physicians.

Program Description

Psoriatic disease is associated with several chronic comorbid conditions including heart disease, metabolic syndrome, diabetes, obesity, malignancies, gastrointestinal disorders, pulmonary disease, chronic kidney disease, and various infectious diseases. Quality of life (qoL) in patients with psoriasis alone is substantially lower than that in patients with other chronic conditions and the combined skin and joint involvement of PsA likely results in further reductions in QoL. The early average age of disease onset suggests patients with psoriatic disease patients will be impacted for a significant proportion of their life. This underscores its relevance to managed care organizations. Considering that patients with psoriasis alone require twice the health care resources over 12 months compared to the general population, it may be inferred that patients with the combination of skin and joint disease incur even greater costs due to the added burden of joint involvement. This symposium is designed to improve knowledge of psoriatic disease and its management among managed care and specialty pharmacy professionals.

Learn About

  • Clinical trial data for existing and emerging psoriatic disease therapies
  • Collaborative treatment decision-making, and treatment optimization via use of specialty pharmacy support services.


Program Manager
Steven Casebeer, MBA
steve.casebeer@impactedu.net

No fee registration:  Coming Soon

Tuesday, Oct. 20 | 1:30 – 3pm


The Gene Therapy Transformation: A Guide for Managed Care Decision Makers

Provided jointly by Postgraduate Institute for Medicine and Impact Education, LLC.
Supported by independent educational grants from bluebird bio and BioMarin.
Continuing education credit available for pharmacists and physicians.

Program Description

Although gene therapy is a promising treatment option for a number of diseases (including inherited disorders, some types of cancer, and certain viral infections), the technique remains risky and is still under investigation to ensure safety and efficacy. Furthermore, research in this field is particularly challenging given the inherent nature of rare diseases and genetic disorders. Approximately 30 million individuals in the United States are living with a rare disease, which by definition have a prevalence of 200,000 or fewer cases in the United States.

Genetic disorders and other rare diseases present unique challenges for health insurers in terms of requisite clinical intervention, disease management, and economic burden. The treatment landscape in US health care has already evolved significantly over the past several decades and appears to be on the precipice of its most groundbreaking innovation to date gene therapy.

Learn About

  • The solutions necessary to address the unique clinical and financial considerations surrounding gene therapies that will ensure quality care and appropriate patient access.


Program Manager
Steven Casebeer, MBA
steve.casebeer@impactedu.net

No fee registration: Coming Soon

Tuesday, Oct. 20 | 4:30 – 6pm


ManagedCareCGM.com Presents: The Value of Continuous Glucose Monitoring in the Advancement of Diabetes Care

Provided jointly by Medical Education Resources, Inc. and Impact Education, LLC.
Supported by an independent educational grant from Dexcom.
Continuing education credit available for pharmacists and physicians.

Program Description

The vast majority of plan members with diabetes have an A1C above ADA targets, putting them at risk for other costly comorbidities. To effectively address these clinical challenges and elicit improvements across 29 indices of glycemic control and glycemic variability, continuous glucose monitoring (CGM) has been endorsed by various professional endocrinology-centered organizations. In 2017, the Centers for Medicare and Medicaid Services (CMS) Medicare made a milestone ruling, establishing benefit coverage for "therapeutic" CGM — a designation applying to those CGM systems approved for use in making treatment decisions without a fingerstick (non-adjunctive use). This program will elucidate the burden of diabetes and describe multifaceted clinical and administrative strategies across the medical and pharmacy benefits to promote quality care and manage costs while improving outcomes for affected plan members.

Learn About

  • Value of real-time CGM in reducing the clinical and economic burden of diabetes
  • Benefit design strategies for accessible and cost-effective care
  • Remote patient monitoring in the hospital setting to support COVID-19 healthcare-related efforts
  • Real-time CGM data and connectivity with the use of telemedicine


Program Manager
Steven Casebeer, MBA
steve.casebeer@impactedu.net

 No fee registration: Coming Soon

Wednesday, Oct. 21 | 7:30 – 9pm


Managing the Cost of C. Difficile Infection: Are You Spending More Than You Know?

Provided jointly by Medical Education Resources, Inc. and Impact Education, LLC
Supported by an independent educational grant from Merck & Co., Inc.
Continuing education credit available for pharmacists and physicians.

Program Description

The incidence of Clostridioides difficile infection or CDI, has increased over the past 2 decades. CDI differs from most other infections because it generally occurs after treatment with antimicrobial therapy. Some of the most commonly associated agents that CDI is associated with include clindamycin, ampicillin, cephalosporins, and fluoroquinolones. It is estimated that CDI costs the U.S. health care system $6 billion every year and average costs per case are more than $20,000.

A CDI expert will review treatment options and engage in peer-to-peer dialogue regarding recent developments and therapeutic recommendations.. Real-world case scenarios will be used to illustrate managed care best practices to evaluate all facets of medical and pharmacy management with initial and recurrent CDI, including assessment of existing and emerging therapies, and appropriate care management strategies to improve overall clinical and economic outcomes.

 Learn About

  • Guideline-based recommendations to elucidate avoidable costs related to the management of CDI that may impact benefit design and coverage decision-making.


Program Manager
Steven Casebeer, MBAsteve.casebeer@impactedu.net

No fee registration: Coming Soon

Thursday, Oct. 22 | 6 – 7:30pm

 

Multiple Sclerosis Management Optimization Strategies for Managed Care and Specialty Pharmacy Professionals

Provided jointly by Postgraduate Institute for Medicine and Impact Education, LLC.
Supported by an independent educational grant from Biogen.
Continuing education credit available for pharmacists.

Program Description

 Multiple sclerosis (MS) is associated with a broad spectrum of comorbid conditions including cardiovascular disease and mental health issues that exert a significant influence on patient morbidity, mortality, and quality of life. Comorbidity is associated with a longer delay between MS symptom onset and diagnosis, more severe disability at diagnosis even after accounting for diagnostic delays, greater disability progression, increased health-care utilization, and higher mortality. More than a dozen disease-modifying therapies (DMTs) are now available for the treatment of MS with several additional novel therapies in late stage development. The abundance of choice can lead to therapeutic inertia or the absence of treatment initiation or intensification when therapeutic goals are unmet. This symposium highlights opportunities for managed care and specialty pharmacy professionals to enhance the management of patients with MS by implementing and/or recommending evidence-driven practices based on current clinical trial data.

Learn About

  • How the rapidly evolving treatment landscape challenges the ability of clinicians and health systems to identify the optimal balance between safety, efficacy, and overall value when making MS treatment decisions


Program Manager
Steven Casebeer, MBA
steve.casebeer@impactedu.net

 No fee registration:   Coming Soon